The human gonadotropin-inhibitory hormone ortholog RFamide-related peptide-3 suppresses gonadotropin-induced progesterone production in human granulosa cells.
RFamide-related peptide-3 (RFRP-3), a mammalian ortholog of avian gonadotropin-inhibitory hormone, has pronounced inhibitory effects on reproduction in a number of species. RFRP-3 suppresses gonadotropin release at the hypothalamic and/or pituitary levels; however, increasing evidence also suggests putative functions within the ovary. We have now demonstrated the expression of both RFRP and its receptor (GPR147) in primary cultures of human granulosa-lutein cells. Immunohistochemical analysis of normal human ovaries from premenopausal women showed that RFRPs and GPR147 were primarily localized in the granulosa cell layer of large preovulatory follicles as well as in the corpus luteum. Treatment of human granulosa-lutein cells with RFRP-3 reduced FSH-, LH- and forskolin-stimulated progesterone production and steroidogenic acute regulatory protein expression but did not affect basal or 8-bromoadenosine 3'5'-cyclic monophosphate stimulated levels. In addition, RFRP-3 inhibited gonadotropin- and forskolin-induced intracellular cAMP accumulation, and these effects were abolished by pretreatment with an inhibitor of inhibitory G(i/o) proteins (pertussis toxin). Importantly, the effects of RFRP-3 on FSH-, LH-, and forskolin-induced cAMP and progesterone accumulation were completely eliminated by cotreatment with the bifunctional GPR147/GPR74 antagonist RF9 or by pretreatment with GPR147 small interfering RNA. These results suggest that RFRP-3 is expressed in human granulosa cells in which it acts via its receptor, GPR147, to inhibit gonadotropin signaling at the level of adenylyl cyclase via activation of a pertussis toxin-sensitive Gα(i/o) protein. This leads to reduced gonadotropin-stimulated cAMP accumulation and progesterone synthesis, likely via reduced steroidogenic acute regulatory protein expression. Thus, ovarian RFRP-3/GPR147 signaling could contribute to normal ovarian function.
Department of Obstetrics and Gynaecology, Child and Family Research Institute, University of British Columbia, 4490 Oak Street, Vancouver, British Columbia, Canada V6H 3V5.
Hajime
H
Oishi
Christian
C
Klausen
George E
GE
Bentley
Tomohiro
T
Osugi
Kazuyoshi
K
Tsutsui
C Blake
CB
Gilks
Tetsu
T
Yano
Peter C K
PC
Leung
D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006023:Glycoproteins / Q000737:chemistry* / Q000494:pharmacology; D006062:Gonadotropins / Q000378:metabolism*; D006107:Granulosa Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D009479:Neuropeptides / Q000494:pharmacology*; D010053:Ovary / Q000378:metabolism; D037342:Pertussis Toxin / Q000494:pharmacology; D017697:Premenopause; D011374:Progesterone / Q000378:metabolism*; D018013:Receptors, Neuropeptide / Q000378:metabolism*
D006023:Glycoproteins; D006062:Gonadotropins; D009479:Neuropeptides; C416987:RFamide peptide; D018013:Receptors, Neuropeptide; C014995:gonadotropin inhibitor; C083929:neuropeptide FF receptor; D005576:Colforsin; D011374:Progesterone; D005640:Follicle Stimulating Hormone; D000242:Cyclic AMP; D037342:Pertussis Toxin